id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1999-D-4088-0002,FDA,FDA-1999-D-4088,Draft Guidance for Industry BA and BE Studies for Orally Administered Drug Products,Other,Guidance,2023-12-13T05:00:00Z,2023,12,2023-12-13T05:00:00Z,,2023-12-13T15:26:51Z,,0,0,09000064804f5ef5
FDA-1999-D-4088-0003,FDA,FDA-1999-D-4088,Request for Extension from National Association of Pharmaceutical Manufacturers,Other,Request for Extension,2023-12-13T05:00:00Z,2023,12,2023-12-13T05:00:00Z,,2023-12-13T15:28:01Z,,0,0,09000064804f5ef7
FDA-1999-D-4088-0001,FDA,FDA-1999-D-4088,Draft Guidance for Industry on BA and BE Studies for Orally Administered Drug Products-General Considerations; Availability,Notice,Notice of Data Availability,2023-12-13T05:00:00Z,2023,12,2023-12-13T05:00:00Z,1999-11-03T04:59:59Z,2023-12-13T15:12:37Z,99-23009,0,0,09000064804f5ef6